Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29684573 | 1.00 | TSHR (0.64) | TSHRCYP3A4TP53ALDH1A1MAOB | |
| Hydrochloric Acid SCHEMBL2480846 | 0.98 | TSHR (0.62) | TSHRCYP3A4TP53ALDH1A1MAOB | |
| SCHEMBL10584943 | 0.95 | TSHR (0.58) | TSHRCYP3A4TP53ALDH1A1MAOB | |
| SCHEMBL16758752 | 0.95 | TSHR (0.58) | TSHRCYP3A4TP53ALDH1A1MAOB | |
| SCHEMBL14839599 | 0.95 | TSHR (0.58) | TSHRCYP3A4TP53ALDH1A1MAOB | |
| SCHEMBL15720636 | 0.95 | TSHR (0.58) | TSHRCYP3A4TP53ALDH1A1MAOB | |
| SCHEMBL2062745 | 0.91 | TSHR (0.67) | TSHRCYP3A4TP53ALDH1A1MAOB | |
| SCHEMBL3791936 | 0.90 | CYP3A4 (0.69) | TSHRCYP3A4TP53ALDH1A1MAOB | |
| SCHEMBL29502076 | 0.90 | CYP3A4 (0.69) | TSHRCYP3A4TP53ALDH1A1MAOB | |
| SCHEMBL15723552 | 0.86 | MAPK1 (0.58) | TSHRCYP3A4TP53ALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3906233-B1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-31 | — | — | EP | disclosed |
| WO-2022199589-A1 | PYRIMIDINE DERIVATIVES | 南京明德新药研发有限公司 | 2022-09-29 | — | — | WO | disclosed |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| WO-2022086892-A1 | INTERLEUKIN 4 (IL4)-INDUCED GENE 1 INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20210403415-A1 | COMPOUNDS AND METHODS TO ATTENUATE TUMOR PROGRESSION AND METASTASIS | THE TRUSTEES OF INDIANA UNIVERSITY | 2021-12-30 | — | — | US | disclosed |
| EP-3906233-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-0783505-B1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 2001-03-07 | — | — | EP | disclosed |
| US-5869485-A | Pyrrolo 2,3-d!pyrimidines and their use | NOVARTIS FINANCE CORP. (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0783505-A1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | Novartis AG (CH) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010028-A1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 1996-04-04 | — | — | WO | disclosed |
| EP-0303360-A1 | Electroconductive polymers | COOKSON GROUP plc (GB) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TSHR 602/4885CYP3A4 2069/4885TP53 2025/4885 |
| US-20210403415-A1 | COMPOUNDS AND METHODS TO ATTENUATE TUMOR PROGRESSION AND METASTASIS | SLC10A1, CCL11, TSG101 | TSHR 4262/4885CYP3A4 2986/4885TP53 16/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | TSHR 1347/4885CYP3A4 2224/4885TP53 961/4885 |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | MAP3K20, MAP3K1, PACSIN2 | TSHR 715/4885CYP3A4 4468/4885TP53 883/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | TSHR 1524/4885CYP3A4 1599/4885TP53 1171/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | TSHR 1524/4885CYP3A4 1599/4885TP53 1171/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | TSHR 1524/4885CYP3A4 1599/4885TP53 1171/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | TSHR 1024/4885CYP3A4 4148/4885TP53 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.